Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Clinical TherapeuticsFree Preview

Fingolimod for Multiple Sclerosis

List of authors.
  • Daniel Pelletier, M.D.,
  • and David A. Hafler, M.D.

A 37-year-old man with multiple sclerosis has recurrent disease activity despite several previous therapies. Treatment with fingolimod is recommended. Fingolimod blocks the egress of lymphocytes from lymph nodes, preventing them from reaching the central nervous system.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Dr. Pelletier reports receiving consulting fees from Synarc, Bayer, Biogen Idec, Genetech, Teva Neuroscience, EMD Serono, Novartis, and Revalesio and grant support from Biogen Idec; and Dr. Hafler, receiving consulting fees from Sanofi-Aventis, McKinsey, NKT Therapeutics, Novartis, Biogen Idec, Teva Neuroscience, and Pfizer and owning stock options in NKT Therapeutics.

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

No other potential conflict of interest relevant to this article was reported.

We thank Dr. Claire Riley and Alyssa Nylander for their critical reading of the manuscript and for assistance with the preparation of the manuscript.

Author Affiliations

From the Yale Multiple Sclerosis Center, Departments of Neurology and Immunobiology, Yale School of Medicine, New Haven, CT.

Address reprint requests to Dr. Pelletier at the Department of Neurology, 15 York St., LLCI-709, P.O. Box 208018, New Haven, CT 06520-8018, or at .

Print Subscriber? Activate your online access.